Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer

被引：0
|
作者：
Kathleen Moore
John K. Chan
Angeles Alvarez Secord
Manish R. Patel
Timothy Callahan
Wei Guo
Zhi-Yi Zhang
机构：
[1] University of Oklahoma HSC,Stephenson Cancer Center
[2] Sarah Cannon Research Institute,Palo Alto Medical Foundation, California Pacific Medical Center
[3] Sutter Health Sutter West Bay,undefined
[4] Duke Cancer Institute,undefined
[5] Florida Cancer Specialists and Research Institute,undefined
[6] BioTel Research,undefined
[7] TESARO,undefined
[8] Inc,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Niraparib; PARP inhibitor; Cardiac repolarization; QTc interval; Ovarian cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：717 / 726
页数：9
相关论文
共 50 条
  • [41] Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer
    Kim, Se Ik
    Lee, Eun Ji
    Lee, Maria
    Chung, Hyunhoon
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong-Sang
    Kim, Hee Seung
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) : 1943 - 1950
  • [42] Secondary Cytoreductive Surgery in the Management of Platinum-Sensitive Recurrent Epithelial Ovarian Cancer
    Park, Jeong-Yeol
    Eom, Jeong-Min
    Kim, Dae-Yeon
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    Nam, Joo-Hyun
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (05) : 418 - 424
  • [43] Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at Hospitals in Spain
    Sagrado, Miguel Angel Rodriguez
    Criado, Javier Alvarez
    Pena, Ainhoa Elisa Arenaza
    Escudero-Vilaplana, Vicente
    Olias, Carlos Folguera
    Fernandez, Marta Herrero
    Martinez Nieto, Concepcion
    Salvador, Ana Rosa Rubio
    Fenollera, Patricia Sanmartin
    Castillo, Maria Jose Vazquez
    TARGETED ONCOLOGY, 2025, : 319 - 327
  • [44] Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
    Shi, Yin
    Xiao, Di
    Li, Shuishi
    Liu, Shao
    Zhang, Yu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [45] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Sabbatini, Paul
    Dupont, Jakob
    Aghajanian, Carol
    Derosa, Felicia
    Poynor, Elizabeth
    Anderson, Sybil
    Hensley, Martee
    Livingston, Phillip
    Lasonos, Alexia
    Spriggs, David
    McGuire, William
    Reinartz, Silke
    Schneider, Sally
    Grande, Cathy
    Lele, Shashikant
    Rodabaugh, Kerry
    Kepner, James
    Ferrone, Soldano
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5503 - 5510
  • [46] DOSE MODIFICATION FOR CHINESE PATIENTS ON NIRAPARIB MAINTENANCE TREATMENT FOR PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A POST HOC ANALYSIS
    Liu, Z.
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Tan, T.
    Dong, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A193 - A194
  • [47] Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US
    Wu, Lei
    Zhong, Lixian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 187 - 195
  • [48] Efficacy and safety of niraparib in platinum-sensitive recurrent ovarian cancer: retrospective observational study in a tertiary hospital
    Prado-Mel, Elena
    Suarez-Casillas, Paloma
    Rodriguez-de Francisco, Lupe
    Estevez-Garcia, Purificacion
    Jimenez-Galan, Rocio
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [49] NEW MAINTENANCE TREATMENT FOR RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2018, 118 (08) : 25 - 26
  • [50] Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
    Zagouri, Flora
    Sergentanis, Theodoros N.
    Chrysikos, Dimosthenis
    Dimopoulos, Meletios-Athanassios
    Bamias, Aristotle
    ONCOTARGETS AND THERAPY, 2015, 8 : 2187 - 2198
12345